TuHURA Biosciences, Inc./NV HURA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $0 | -$30.1M | — | -$27.7M | $20.9M |
| 2024 | $0 | -$21.7M | — | -$14.8M | $14.6M |
| 2024 | — | -$8.3M | — | — | -$7.0M |
| 2023 | $0 | -$29.3M | — | -$12.0M | -$1.6M |
| 2023 | — | -$14.6M | — | — | $731,000 |
| 2022 | — | -$22.7M | — | -$20.6M | $11.8M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Bianco James A. | Chief Executive Officer | 2026-05-28 | Gift | 150,000 | — |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Source: SEC EDGAR filings · CIK 0001498382 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.